Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA profiles of primary AML cells engrafted in xenograft mouse model

ABSTRACT: RNA profiles of primary AML cells engrafted in xenograft mouse model

PROVIDER: PRJNA835091 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR19084469_1.fastq.gz	Fastqsanger.gz
	SRR19084469_2.fastq.gz	Fastqsanger.gz
	SRR19084470_1.fastq.gz	Fastqsanger.gz
	SRR19084470_2.fastq.gz	Fastqsanger.gz
	SRR19084471_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 24

Similar Datasets

RNA profiles of primary AML cells engrafted in xenograft mouse model

Project description:RNA-seq analysis of RNAs isolated from primary FLT3-ITD+ AML cells in the spleen and bone marrow from xenograft mouse model after 16 hours of treatment with FLT3 inhibitor AC220 (quizartinib)

2022-10-19 | GSE202222 | GEO

RNA sequencing of patient derived xenograft sample AML-346, AML-356, AML-388 and AML-661 using prime-seq

Project description:RNA sequencing of patient derived xenograft sample AML-346, AML-356, AML-388 and AML-661 using prime-seq

| PRJNA890685 | ENA

A T-cell receptor targeting a shared neoantigen mediates elimination of primary human acute myeloid leukemia in vivo

Project description:This paper presents a T-cell receptor (TCR) reactive to the recurrent D835Y driver mutation in the FLT3 tyrosine-kinase domain. TCRFLT3D/Y-redirected T cells selectively eliminated primary human AML cells harboring the D835Y mutation in vitro and in vivo. The TCRFLT3D/Y cells rejected both CD34+ and CD34- AML in mice engrafted with primary leukemia from patients, reaching minimal residual disease negative levels, and eliminated primary CD34+ AML leukemia-propagating cells in vivo. Thus, T cells targeting a single shared mutation can provide efficient immunotherapy towards selective elimination of clonally involved primary AML cells in vivo.

2023-08-28 | PXD043908 | Pride

Gene expression in primary AML patients

Project description:Gene expression in primary AML patients

| PRJNA662305 | ENA

mRNA profiling in primary AML cells

Project description:mRNA profiling in primary AML cells

| PRJNA779734 | ENA

Effects of Beta Catenin antagonist BC2059 in AML cells

Project description:To determine the global transcriptomic changes induced by treatment with the Beta Catenin antagonist BC2059 in AML cells The canonical WNT-β-catenin pathway is essential for self-renewal, growth and survival of AML stem/blast progenitor cells (BPCs). Deregulated WNT signaling inhibits degradation of β-catenin, causing increased nuclear translocation and co-factor activity of β-catenin with the transcriptional regulator TCF4/LEF1 in AML BPCs. Here, we determined the pre-clinical anti-AML activity of the anthraquinone oxime-analog BC2059 (BC), known to attenuate β-catenin levels. BC treatment disrupted the binding of β-catenin with the scaffold protein TBL1 (transducin β-like 1) and proteasomal degradation and decline in the nuclear levels of β-catenin. This was associated with reduced transcriptional activity of TCF4 and expression of its target genes, cyclin D1, c-Myc and survivin. BC treatment dose-dependently induced apoptosis of cultured and primary AML BPCs. Treatment with BC also significantly improved the median survival of immune-depleted mice engrafted with either cultured or primary AML BPCs exhibiting nuclear expression of β-catenin. Co-treatment with the pan-histone deacetylase inhibitor panobinostat and BC synergistically induced apoptosis of cultured and primary AML BPCs, including those expressing FLT3-ITD, as well as further significantly improved the survival of immune-depleted mice engrafted with primary AML BPCs. These findings underscore the promising pre-clinical activity and warrant further testing of BC against human AML, especially those expressing FLT3-ITD.

2014-12-31 | GSE61275 | GEO

DNR pulse treatment of primary AML

Project description:Primary human AML bone marrow sample (newly diagnosed, prior to treatment initation) was obtained from donor after consent and AML blasts were isolated by standard Ficoll centrifugation. AML blasts were pulse-treated with daunorubicine (100 nM, 200 nM, 400 nM) or DMSO control for 1 hour, followed by wash-out and short-term cell culture to allow cellular responses to develop. 20,000 cells were analysed by LC-MS3, and 5,000 cells were subjected to flow cytometry apoptosis assay.

2022-10-15 | PXD030280 | Pride

Transcriptomic profiling of human AML cell lines and primary AML samples

Project description:We sequenced mRNA from both cell lines and primary samples to investigate transcriptomic profiles of human AML cell lines and primary samples. We then performed gene expression profiling analysis using data obtained from RNA-seq of AML cell lines and primary samples that have sphingolipidomic characterization to identify transcriptional differences between two distinct sphingolipidomic subtypes in AML samples.

2024-01-14 | GSE229032 | GEO

Transcriptomic profiling of human AML cell lines and primary AML samples

Project description:Transcriptomic profiling of human AML cell lines and primary AML samples

| PRJNA952616 | ENA

microRNA expression profiles of prostate cancer xenograft model

Project description:In order to investigate the role of microRNAs in the progression of CRPC, we evaluated expression profiles by microarray analysis of microRNAs derived from xenograft tumor tissues obtained at the CRPC stage in comparison to those at an androgen dependent stage. We evaluated expression profiles of microRNAs derived from the KUCaP2 xenograft tumor tissues at the CRPC stage in comparison to those at the androgen dependent stage (n=4) by microRNA microarray analysis.

2014-03-13 | E-GEOD-55829 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data